Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Structured assessment and followup for patients with hereditary kidney tumour syndromes.

Lattouf JB, Pautler SE, Reaume MN, Kim RH, Care M, Green J, So A, Violette PD, Saliba I, Major P, Silver S, Leicht R, Basiuk J, Tanguay S, Jewett MA, Drachenberg D; Kidney Cancer Research Network of Canada..

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E214-E222. doi: 10.5489/cuaj.3798.

2.

Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management.

Gaur S, Turkbey B, Choyke P.

Semin Ultrasound CT MR. 2017 Feb;38(1):59-71. doi: 10.1053/j.sult.2016.10.002.

PMID:
28237281
3.

Basic Parameters of Blood Count as Prognostic Factors for Renal Cell Carcinoma.

Prokopowicz G, Życzkowski M, Nowakowski K, Bogacki R, Bryniarski P, Paradysz A.

Biomed Res Int. 2016;2016:8687575. doi: 10.1155/2016/8687575.

4.

Genetic predisposition to kidney cancer.

Schmidt LS, Linehan WM.

Semin Oncol. 2016 Oct;43(5):566-574. doi: 10.1053/j.seminoncol.2016.09.001. Review.

PMID:
27899189
5.

Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes.

Watson MJ, Sidana A, Diaz AW, Siddiqui MM, Hankins RA, Bratslavsky G, Linehan WM, Metwalli AR.

J Endourol. 2016 Nov;30(11):1219-1226.

PMID:
27650937
6.
7.

Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Manley BJ, Hakimi AA.

Curr Opin Urol. 2016 Sep;26(5):383-7. doi: 10.1097/MOU.0000000000000307.

PMID:
27467134
8.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188.

PMID:
27457310
9.

High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.

Xi W, Liu L, Wang J, Xia Y, Bai Q, Long Q, Wang Y, Xu J, Guo J.

Sci Rep. 2016 Jul 6;6:29177. doi: 10.1038/srep29177.

10.

Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

Tran TA, Leong HS, Pavia-Jimenez A, Fedyshyn S, Yang J, Kucejova B, Sivanand S, Spence P, Xie XJ, Peña-Llopis S, Power N, Brugarolas J.

Mol Cell Biol. 2016 Jun 15;36(13):1836-55. doi: 10.1128/MCB.00189-16.

11.

Metabolism-related enzyme alterations identified by proteomic analysis in human renal cell carcinoma.

Lu Z, Yao Y, Song Q, Yang J, Zhao X, Yang P, Kang J.

Onco Targets Ther. 2016 Mar 9;9:1327-37. doi: 10.2147/OTT.S91953.

12.

Bioinformatics analysis and expression study of fumarate hydratase in lung cancer.

Ming Z, Jiang M, Li W, Fan N, Deng W, Zhong Y, Zhang Y, Zhang Q, Yang S.

Thorac Cancer. 2014 Nov;5(6):543-9. doi: 10.1111/1759-7714.12127.

13.

Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer.

Liu L, Liu Y, Zhang T, Wu H, Lin M, Wang C, Zhan Y, Zhou Q, Qiao B, Sun X, Zhang Q, Guo X, Zhao G, Zhang W, Huang W.

J Exp Clin Cancer Res. 2016 Jan 8;35:3. doi: 10.1186/s13046-015-0279-6.

14.

Renal cell carcinoma risk is associated with the interactions of APOE, VHL and MTHFR gene polymorphisms.

Lv C, Bai Z, Liu Z, Luo P, Zhang J.

Int J Clin Exp Pathol. 2015 May 1;8(5):5781-6.

15.

Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.

Sankin A, Hakimi AA, Hsieh JJ, Molina AM.

Front Oncol. 2015 Apr 8;5:67. doi: 10.3389/fonc.2015.00067. Review.

16.

The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.

Tomczak K, Czerwińska P, Wiznerowicz M.

Contemp Oncol (Pozn). 2015;19(1A):A68-77. doi: 10.5114/wo.2014.47136. Review.

17.

Identification of genes and pathways involved in kidney renal clear cell carcinoma.

Yang W, Yoshigoe K, Qin X, Liu JS, Yang JY, Niemierko A, Deng Y, Liu Y, Dunker A, Chen Z, Wang L, Xu D, Arabnia HR, Tong W, Yang M.

BMC Bioinformatics. 2014;15 Suppl 17:S2. doi: 10.1186/1471-2105-15-S17-S2.

18.

Genomic investigation of etiologic heterogeneity: methodologic challenges.

Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, Rathmell WK, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ.

BMC Med Res Methodol. 2014 Dec 22;14:138. doi: 10.1186/1471-2288-14-138.

19.

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.

Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, Bjarnason GA, Pili R.

Mol Cancer Ther. 2015 Feb;14(2):513-22. doi: 10.1158/1535-7163.MCT-14-0208.

20.

A Case of Reed's Syndrome: An Underdiagnosed Tumor Disorder.

Kontochristopoulos G, Kouris A, Balamoti E, Vavouli C, Markantoni V, Christofidou E, Antoniou C.

Case Rep Dermatol. 2014 Jul 25;6(2):189-93. doi: 10.1159/000365862.

Supplemental Content

Support Center